Recently, a large-scale medical study completed in Hubei Province, China, showed that women collected menstrual blood at home for HPV testing, and its screening effect on cervical precancerous lesions was comparable to the current clinician sampling method in hospitals. This discovery provides a new path for cervical cancer screening to be more convenient and private.

Obstetrics and gynecology, as a key field to protect women's health and the birth of new life, has ushered in a series of breakthroughs between 2025 and 2026. From innovative drugs for hypertension in pregnancy, to new treatment strategies for endometriosis, to major breakthroughs in gynecological tumor immunotherapy and the deep integration of artificial intelligence (AI) in clinical applications, these cutting-edge studies not only bring new solutions to clinical practice, but also point out the direction for future medical development. This article will systematically review the recent key research results in the field of obstetrics and gynecology and explore their clinical significance and future prospects.

The field of endometriosis is undergoing a profound transformation from concept to practice. In 2025, the field of internal dysmorphosis will make systematic progress from pathogenesis to clinical diagnosis and treatment at three major international conferences (WCE, ACE, SEUD). Driven by the consensus of international conferences, its diagnosis and treatment model has fully shifted to patient-centered lifecycle management. Obstetrics and Gynecology Network specially invited Professor Xu Hong from the International Peace Maternal and Child Health Hospital Affiliated to Shanghai Jiao Tong University School of Medicine to conduct in-depth interpretation and outlook on core topics such as the new progress of the annual international conference, the "dual-track strategy" of the management of internal diseases and chronic diseases, and how China can enhance its international discourse.

As a common gynecological malignant tumor, the diagnosis and treatment strategy of endometrial cancer is undergoing profound changes with the advancement of molecular biology and immunotherapy. In 2025, a number of guidelines and clinical studies at home and abroad will further promote the precision and individualization of disease management. The Obstetrics and Gynecology Network is honored to invite Professor Cao Dongyan of Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences to sort out the important progress in the past year in the molecular stratification of early postoperative adjuvant treatment of endometrial cancer, the establishment of first-line standards for advanced immunization combined with chemotherapy, the expansion of the target immunity combined with "de-chemotherapy" model, and the exploration of back-line treatment for patients with refractory relapse.

In 2025, the field of Antibody-Drug Conjugates (ADCs) for gynecological tumors entered a critical period of target refinement and clinical translation. Vedetuximab was approved for the cervical cancer indication, while research on classic targets such as HER2 and FRα added significant new data. Breakthroughs were made in the exploration of novel targets, and domestic expert consensus was simultaneously established, marking the transition of this field from clinical exploration to standardized application. Obstetrics and Gynecology Network invited Professor Zhou Jinhua from the First Affiliated Hospital of Soochow University to systematically review the year's core progress and look ahead to the future direction of the field from three dimensions: the development history of ADCs, target exploration, and future innovations, providing professional reference for clinical diagnosis and treatment.

List of the 13th Committee of the CMA Society of Obstetrics and Gynaecology Released; Academician Zhu Lan Appointed Chairperson

On January 30, 2026, Elsevier, a world-renowned information analysis agency, officially announced the 2025 list of "China's Highly Cited Scholars".

2025 Year-End Review – Professor Zang Rongyu: "Hardcore Data" Validates the Value of Surgery, Chinese Standards Pave a New Journey for Ovarian Cancer Diagnosis and Treatment

2025 Year-End Review – Professor Li Li: From Norm Popularization to Precision Treatment, Reviewing the Annual Advances in Cervical Cancer Diagnosis and Treatment

Professor Di Wen, Research Fellow Yang Fan, Research Fellow Zhuang Guanglei, and other scholars from Renji Hospital, Shanghai Jiao Tong University School of Medicine, jointly published a landmark research achievement in Nature Biomedical Engineering (IF=26.6). The team independently developed a novel trispecific antibody, B7H3xCD3xPDL1, which innovatively integrates three core functions: tumor targeting, T cell activation, and immune microenvironment remodeling. Through a unique IFNγ-IL-15 positive feedback loop, the antibody successfully activates bystander T cells in the tumor microenvironment and reverses the immunosuppressive state, thereby providing an entirely new therapeutic approach for intractable solid tumors such as ovarian cancer and colorectal cancer. This groundbreaking achievement has garnered high recognition from the global academic community.